Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highlighted in the look-back and look-ahead on an earnings call,

Johnson & Johnson unveiled financial results that beat Wall Street expectations as the company braces for one of its top-selling medicines, Stelara, to go off patent in the coming weeks.Fourth-quarter sales,

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee

Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data centers in the U.S.

Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2 per share in its forthcoming report, representing a decline of 12.7% year over year. Revenues ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price target - 13% upside

Wall Street indexes hit new highs, driven by optimism in tech stocks, following President Trump's announcement of a $500 billion AI infrastructure plan. Netflix soared on strong subscriber numbers, while semiconductor shares surged on AI excitement.

Johnson & Johnson expects full-year earnings in the range of $10.50 to $10.70 per share, with revenue in the range of $89.2 billion to $90 billion. This story was generated by Automated Insights ( http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on JNJ at https://www.zacks.com/ap/JNJ

NEW YORK — Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies. The health care giant said Jan. 13 that it will pay $132 in cash per share, or a 39 percent premium from Friday's closing price.

A new Wall Street Journal report says there are a few reasons why a company might list a job, but never follow through and hire someone.

Companies are posting robust results so far this earnings season, but the bar is high for stock gains to continue.

We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against Prem Watsa’s other long-term stock picks.